Esperion Therapeutics' Acquisition

Esperion Therapeutics was acquired by Pfizer on February 16, 2004.

Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase i…

Articles about Esperion Therapeutics' Acquisition: